预约演示
更新于：2026-08-29
Lixisenatide
利司那肽
更新于：2026-08-29
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 欧盟 (2013-01-31), |
最高研发阶段(中国)撤市 |
特殊审评- |
登录后查看时间轴
结构/序列
Sequence Code 25682
来源: *****
关联
76
项与 利司那肽 相关的临床试验NCT07173712
Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes Mellitus Patients With Inadequate Glycemic Control on Oral Hypoglycemic Agents: A Multicenter, Open-Label, Randomized Controlled Study
NCT07117240
Efficacy of Treatment Strategies for Steroid-induced Diabetes - a Comparison of GLP-1 Receptor Agonist Plus Basal Insulin With Intensive Insulin Therapy
CTRI/2024/10/075222
A Multicentre Phase IV single arm clinical trial to evaluate the safety and efficacy of a fixed ratio combination of Insulin Glargine and Lixisenatide in adult patients with Type 2 diabetes who are sub optimally controlled on oral anti-hyperglycemic drugs and/or basal Insulin/GLP-1 RA - iGlarLixi Phase 4 study in India
100 项与 利司那肽 相关的临床结果
登录后查看更多信息
100 项与 利司那肽 相关的转化医学
登录后查看更多信息
100 项与 利司那肽 相关的专利（医药）
登录后查看更多信息
563
项与 利司那肽 相关的文献（医药）2026-09-01PHARMACOLOGICAL RESEARCH
GLP-1 receptor agonist therapy in children and adolescents with obesity: A network meta-analysis of differential cardiometabolic efficacy and safety profiles
Article
作者: Qin, Muting ; Li, Yao ; Tuersun, Adili ; Chen, Huanxue ; Fan, Xichen ; Xing, Haoyue ; Xu, Xiaoou ; Zhao, Xin ; Abuduaini, Subinuer
IMPORTANCE:
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used in adolescents with overweight or obesity, but their comparative effects on cardiometabolic outcomes across different agents remain uncertain. We aimed to compare the efficacy and safety of different GLP-1RAs on key cardiometabolic parameters in adolescents with overweight or obesity, with or without type 2 diabetes.
METHODS:
We searched PubMed, Embase, Web of Science, the Cochrane Library, and ClinicalTrials.gov from inception to May 1, 2026. Randomised clinical trials comparing GLP-1RAs with placebo or another active agent in eligible adolescents were included. Two reviewers independently extracted data and assessed risk of bias following PRISMA guidelines for network meta-analysis. We used a Bayesian random-effects model for data synthesis.
RESULTS:
17 RCTs with 1230 participants were included. Semaglutide 2.4 mg SC was associated with the largest reductions in body weight (mean difference -18.00 kg; 95% credible interval -24.34 to -11.69, high confidence), BMI (-5.9 kg/m2, -10.5 to -1.3, high confidence), and waist circumference (-12.2 cm, -21.67 to -2.67). For glycaemic control, dulaglutide 1.5 mg SC showed the largest reduction in HbA1c (-1.50%, -1.84 to -1.15, high confidence), and lixisenatide 20 ug SC showed the largest reduction in fasting plasma glucose (-3.98 mmol/L, -7.46 to -0.60); however, these rankings derive from networks with sparse head-to-head evidence and wide credible intervals for indirect comparisons. Exenatide 20 ug SC was associated with a reduction in systolic blood pressure (-6.64 mmHg, -13.22 to -0.17) based on limited indirect evidence from early-phase trials. No agent improved lipid profiles in a statistically significant manner.
CONCLUSION:
In this network meta-analysis of adolescents with overweight or obesity, GLP-1RAs showed differential cardiometabolic profiles. Semaglutide 2.4 mg produced the largest point estimates for weight-related outcomes, dulaglutide 1.5 mg and lixisenatide 20 ug for glycaemic endpoints, and exenatide 20 ug for systolic blood pressure. These findings are hypothesis-generating: most active-treatment comparisons were indirect, many nodes were informed by single trials, and SUCRA rankings should not be interpreted as evidence of definitive clinical superiority.
2026-08-01AMERICAN JOURNAL OF OPHTHALMOLOGY
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients With Type 2 Diabetes and Diabetic Retinopathy
Article
作者: Dani, Sourbha S ; Verma, Anushka ; Ganatra, Sarju ; Patel, Tirth ; Panchal, Krisha ; Ramsey, Kathryn Moynihan ; Patel, Vahin ; Upadhyay, Jagriti ; Shah, Jui ; Makwana, Bhargav ; Ramsey, David J ; Kong, Yixin ; Khadke, Sumanth ; Vivekanandan, Suja
PURPOSE:
To evaluate the association of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) use on macrovascular and microvascular outcomes in patients with type 2 diabetes (T2D) and diabetic retinopathy (DR)-a high-risk group often excluded from clinical trials.
DESIGN:
Retrospective, population-based cohort study.
PARTICIPANTS:
Adults aged ≥18 years with T2D (with hemoglobin A1c of ≥6.5%) and a pre-existing diagnosis of DR from the TriNetX research network database between January 1, 2015, and December 31, 2022.
METHODS:
The study included 173,216 adults with T2D, all of whom had DR, adjusted for baseline characteristics through propensity score matching (PSM) based on whether the individuals received at least 2 prescriptions of a GLP-1 RA (semaglutide, dulaglutide, liraglutide, exenatide, tirzepatide, or lixisenatide) at least 6 months apart.
MAIN OUTCOME MEASURES:
Cox proportional hazard regression models were used to evaluate the association between GLP-1 RAs and the risk of incident macrovascular and microvascular complications over a 2-year follow-up period.
RESULTS:
After PSM, 30,613 individuals (mean [SD] age, 61.6 [11.4] years; 53.2% were females) were prescribed GLP-1 RAs. Patients on GLP-1 RAs had a decreased risk of myocardial infarctions (MIs; hazard ratio [HR], 0.65; 95% CI, 0.61-0.69), coronary artery revascularization procedures (HR, 0.75; 95% CI, 0.67-0.84), heart failure exacerbations (HR, 0.78; 95% CI, 0.76-0.81), ischemic strokes (HR, 0.78; 95% CI, 0.74-0.83), lower extremity amputations (HR, 0.78; 95% CI, 0.69-0.88), acute kidney injuries (AKI; HR, 0.68; 95% CI, 0.66-0.71), or the need for renal replacement therapy (RRT; HR, 0.40; 95% CI, 0.36-0.43). Fewer individuals also progressed to proliferative diabetic retinopathy (HR, 0.78; 95% CI, 0.71-0.86), experienced retinal vein occlusions (RVOs; HR, 0.70; 95% CI, 0.61-0.80), or developed neovascular glaucoma (HR, 0.65; 95% CI, 0.47-0.89); no association was observed for retinal artery occlusions (RAOs; HR, 0.85; 95% CI, 0.57-1.26) or cases of non-arteritic ischemic optic neuropathy (NAION; HR, 0.88; 95% CI, 0.54-1.44).
CONCLUSIONS:
In patients with T2D and pre-existing DR, the use of GLP-1 RAs was associated with a reduced risk of major macrovascular and microvascular complications, including those directly affecting the retina. Future studies are needed to assess the extent to which GLP-1 RAs benefit long-term outcomes.
2026-08-01Epilepsy Currents
The Effect of GLP-1 Receptor Agonists on Epilepsy: No Appetite for Seizures
Article
作者: Karakis, Ioannis
Association Between GLP-1 Receptor Agonist Use and Epilepsy Risk in Type 2 Diabetes
Cheng CY, Lo SC, Huang CN, Yang YS, Wang YH, Kornelius E.
Neurology
. 2026;106(1):e214509. doi:10.1212/WNL.0000000000214509. Epub 2025 Dec 10. PMID: 41370744.
Background and Objectives: Individuals with type 2 diabetes mellitus (T2DM) are at an increased risk of developing epilepsy, particularly in later life. While preclinical studies suggest neuroprotective properties of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), real-world comparative effectiveness data remain limited. We aimed to evaluate whether GLP-1 RA use is associated with a lower risk of incident epilepsy compared with dipeptidyl peptidase-4 inhibitor (DPP-4i) use in adults with T2DM. Methods: We conducted a retrospective cohort study using the TriNetX network from 2015 to 2023, including adults aged 18 years or older with T2DM who were new users of either GLP-1 RAs or DPP-4is. Patients with a previous diagnosis of epilepsy or seizure, or those using antiepileptic drugs, were excluded. The primary outcome was incident epilepsy, identified using ICD-10-CM codes. Propensity score matching (1:1) was performed based on demographics, socioeconomic status, body mass index, comorbidities, and baseline medications. Cox proportional hazard models estimated hazard ratios (HRs) with 95% confidence intervals (CIs). We also conducted prespecified subgroup and sensitivity analyses to assess the robustness of the findings. Results: After matching, 452 766 patients were included (226 383 in each group; mean age 60.5 years; 47.1% female). During follow-up, 1670 individuals in the GLP-1 RA group and 1886 in the DPP-4i group developed epilepsy, corresponding to cumulative incidences of 2.35% versus 2.41%. Glucagon-like peptide-1 receptor agonists use was associated with a significantly lower risk of epilepsy (HR 0.84, 95% CI 0.78-0.90), with protective associations evident at 1 year (HR 0.71, 95% CI 0.62-0.80), 3 years (HR 0.81, 95% CI 0.74-0.88), and 5 years (HR 0.82, 95% CI 0.76-0.88). Among individual agents, semaglutide showed the strongest association (HR 0.68, 95% CI 0.60-0.77). The results were consistent across major subgroups, including both age and sex. Sensitivity analyses excluding patients with overlapping or switching exposure yielded similar findings (HR 0.71, 95% CI 0.64-0.78). Discussion: Glucagon-like peptide-1 receptor agonists therapy was associated with a significantly lower epilepsy risk compared with DPP-4i use in adults with T2DM. These results support the hypothesis that GLP-1 RAs may exert neurologic benefits beyond glycemic control. Limitations include the observational design and potential residual confounding.Seizure Recurrence after GLP-1 Receptor Agonist Initiation in Adults with Epilepsy
AbuAlrob MA, Hussein A, Abdellatif R, Itbaisha A, Zammar K, Mesraoua B.
Epilepsia
. 2025. doi:10.1111/epi.70022. Epub ahead of print. PMID: 41251033.
Objective: To examine whether initiation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with seizure recurrence and related outcomes in adults with epilepsy and type 2 diabetes. Methods: We conducted a retrospective cohort study using de-identified electronic health records from the TriNetX Research Network (January 2003-August 2025), including adults ≥18 years with ≥3 epilepsy or recurrent seizure diagnoses. Patients initiating a GLP-1 RA (exenatide, liraglutide, dulaglutide, lixisenatide, semaglutide, or tirzepatide) without prior comparator therapy were compared with those initiating other glucose-lowering agents (sodium–glucose cotransporter 2 inhibitors, dipeptidyl peptidase 4 inhibitors, sulfonylureas, or insulin) without GLP-1 RA exposure. Propensity score matching (1:1) was performed on 82 covariates, yielding 8688 matched pairs. Outcomes were assessed using Cox proportional hazards models. Results: After matching, the mean age was 52.6 years, and 67.6% were female. Median follow-up was 514 days (interquartile range [IQR] 671) for GLP-1 RA initiators and 415 days (IQR 769) for comparators. Glucagon-like peptide-1 receptor agonists initiation was associated with lower risk of seizure recurrence (HR 0.82, 95% confidence interval [CI] 0.78-0.86; RD −2.1%), hospitalization (HR 0.35, 95% CI 0.29-0.43;
RD −2.6%), and all-cause mortality (HR 0.40, 95% CI 0.34-0.47; RD −4.8%). Associations with status epilepticus (HR 0.75, 95% CI 0.66-0.85; RD −0.7%) and ICU admission (HR 0.82, 95% CI 0.69-0.96; RD −0.3%) were smaller; the latter was not statistically significant. Significance: In this large multinational cohort, GLP-1 RA initiation was associated with reduced risks of seizure recurrence, hospitalization, and mortality compared with other glucose-lowering therapies. These hypothesis-generating findings warrant confirmation in prospective studies before translation into clinical practice.
100 项与 利司那肽 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 2型糖尿病 | 欧盟 | 2013-01-31 | |
| 2型糖尿病 | 冰岛 | 2013-01-31 | |
| 2型糖尿病 | 列支敦士登 | 2013-01-31 | |
| 2型糖尿病 | 挪威 | 2013-01-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性冠状动脉综合征 | 临床3期 | 美国 | 2010-06-01 | |
| 急性冠状动脉综合征 | 临床3期 | 中国 | 2010-06-01 | |
| 急性冠状动脉综合征 | 临床3期 | 日本 | 2010-06-01 | |
| 急性冠状动脉综合征 | 临床3期 | 阿根廷 | 2010-06-01 | |
| 急性冠状动脉综合征 | 临床3期 | 澳大利亚 | 2010-06-01 | |
| 急性冠状动脉综合征 | 临床3期 | 奥地利 | 2010-06-01 | |
| 急性冠状动脉综合征 | 临床3期 | 白俄罗斯 | 2010-06-01 | |
| 急性冠状动脉综合征 | 临床3期 | 比利时 | 2010-06-01 | |
| 急性冠状动脉综合征 | 临床3期 | 巴西 | 2010-06-01 | |
| 急性冠状动脉综合征 | 临床3期 | 保加利亚 | 2010-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | GLP-1 receptor agonists (GLP-1RAs) | 顧糧觸糧憲齋糧鏇築醖(糧廠網獵範醖製網襯夢) = 膚構鑰鑰齋醖觸齋製構 廠顧築網蓋醖築壓範顧 (膚願餘願壓觸鏇齋餘襯 ) | 不佳 | 2025-02-13 | ||
Placebo/non-GLP-1 RA regimens | 顧糧觸糧憲齋糧鏇築醖(糧廠網獵範醖製網襯夢) = 膚製鬱鏇遞餘糧鏇壓膚 廠顧築網蓋醖築壓範顧 (膚願餘願壓觸鏇齋餘襯 ) | ||||||
临床2期 | 156 | 鏇積鹹範醖繭鹽鏇糧製(鏇選膚淵獵鬱選鏇鹽鏇) = Nausea occurred in 46% of participants receiving lixisenatide 蓋範襯鬱醖蓋壓網顧鏇 (願願衊獵製壓願願糧觸 ) 更多 | 积极 | 2024-04-04 | |||
Placebo | |||||||
临床2期 | 156 | 繭鑰範製繭獵淵鑰夢憲(窪廠蓋艱糧糧廠壓遞窪) = 願築顧鬱糧遞夢糧築壓 鹹艱餘壓夢壓憲獵窪窪 (衊製餘選製憲襯構艱淵 ) 更多 | 积极 | 2024-04-03 | |||
Placebo | 繭鑰範製繭獵淵鑰夢憲(窪廠蓋艱糧糧廠壓遞窪) = 網窪簾窪鏇築鑰夢憲膚 鹹艱餘壓夢壓憲獵窪窪 (衊製餘選製憲襯構艱淵 ) 更多 | ||||||
临床3期 | - | iGlarLixi | 壓獵廠襯淵鏇遞願蓋鏇(鬱廠壓艱鬱襯餘簾範鑰): P-Value = 11.45 | - | 2023-03-30 | ||
Glargine 100 U/mL | |||||||
临床3期 | 426 | iGlarLixi | 鑰繭膚壓夢糧範鏇淵積(夢簾繭夢築築淵膚膚積) = 構憲築齋鑰壓觸鹽鬱夢 選鹽鑰艱蓋遞觸鏇範衊 (繭壓簾範觸鏇鹽鏇顧壓 ) 更多 | 优效 | 2022-06-28 | ||
insulin glargine | 鑰繭膚壓夢糧範鏇淵積(夢簾繭夢築築淵膚膚積) = 窪醖願鹹選艱繭廠蓋顧 選鹽鑰艱蓋遞觸鏇範衊 (繭壓簾範觸鏇鹽鏇顧壓 ) 更多 | ||||||
STAR.Ro (Pubmed) 人工标引  | N/A | 901 | 齋淵觸廠夢齋繭願築遞(壓窪製鑰選艱餘憲壓齋) = 鏇觸繭製顧夢鹽壓艱蓋 窪繭獵餘網積鬱齋齋餘 (鬱繭選鏇顧築觸廠願淵, -1.4 ~ -1.2) 更多 | 积极 | 2022-05-27 | ||
临床3期 | 878 | iGlarLixi | 網鏇願獵鑰簾積願齋簾(淵糧築獵鹽選顧憲壓鬱) = 餘觸簾觸醖夢築膚遞積 廠膚範選憲範簾蓋鑰餘 (顧網壓築觸夢簾鏇繭衊 ) 更多 | 积极 | 2022-04-19 | ||
Insulin glargine 100 U/mL | 網鏇願獵鑰簾積願齋簾(淵糧築獵鹽選顧憲壓鬱) = 壓築壓簾範選襯範鏇製 廠膚範選憲範簾蓋鑰餘 (顧網壓築觸夢簾鏇繭衊 ) | ||||||
临床1期 | 57 | 製膚構壓築繭齋鏇範襯(鹹廠獵夢艱築衊鏇襯壓) = 範願製鏇鑰艱淵壓鹽積 觸遞簾壓簾顧鹹糧構襯 (遞選窪鏇廠製繭襯簾構 ) 更多 | 积极 | 2020-09-24 | |||
製膚構壓築繭齋鏇範襯(鹹廠獵夢艱築衊鏇襯壓) = 齋簾繭壓遞顧襯窪廠選 觸遞簾壓簾顧鹹糧構襯 (遞選窪鏇廠製繭襯簾構 ) | |||||||
临床1期 | 57 | 壓範窪壓遞製衊構艱鑰(窪製觸鏇淵廠網艱鏇襯) = 鹹憲糧艱築鬱窪積願壓 醖醖網蓋顧願範糧壓範 (壓顧膚衊餘廠憲網襯餘, -40.6, ~ 0.8) 更多 | - | 2020-07-09 | |||
願鹽製鑰顧鹽夢構構網(獵醖鹽窪齋顧鹹製餘簾) = 製壓築積壓鹽醖鹹鬱築 範壓蓋鹽網餘繭襯廠願 (齋壓積夢艱繭夢鏇選網, 3 ~ 46) | |||||||
N/A | 12 | 觸願鏇觸餘廠選壓淵築(夢窪範積選繭築衊鹹壓) = 淵製鏇糧鹹膚夢衊窪醖 衊簾鏇餘繭餘獵選範網 (簾夢構積願獵顧積艱築 ) 更多 | - | 2020-07-01 | |||
Placebo | 觸願鏇觸餘廠選壓淵築(夢窪範積選繭築衊鹹壓) = 簾鏇範網齋製範齋憲鹹 衊簾鏇餘繭餘獵選範網 (簾夢構積願獵顧積艱築 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用